Abstract: The invention provides a method of reducing anxiety and/or depression in a subject comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to reduce anxiety and/or depression in a subject in the subject.
Type:
Application
Filed:
September 15, 2017
Publication date:
December 3, 2020
Applicant:
PRILENIA THERAPEUTICS DEVELOPMENT LTD
Inventors:
Michael HAYDEN, Mahmoud Abdulhossein POULADI
Abstract: The invention provides a method of treating a subject afflicted with a drug-induced movement disorder including levodopa-induced dyskinesia comprising periodically administering to the subject in need thereof an amount of pridopidine effective to treat the subject. The invention further provides a method of treating a subject at risk of developing a drug-induced movement disorder, including levodopa-induced dyskinesia. The invention also provides pharmaceutical compositions suitable for carrying out these methods and packages containing such pharmaceutical compositions.
Type:
Application
Filed:
April 8, 2019
Publication date:
August 1, 2019
Applicant:
PRILENIA THERAPEUTICS DEVELOPMENT LTD.
Inventors:
Michal GEVA, Aric Orbach, Michael Hayden
Abstract: The subject invention provides a modified release solid oral dosage form comprising a therapeutically effective amount of Pridopidine or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable rate controlling excipient, wherein the solid oral dosage form provides an in vivo plasma pridopidine concentration profile having a Mean Cmax of about 1,400 ng/ml or less. The subject invention also provides a method of treating an individual afflicted with a neurodegenerative disease or disease related to dopamine, comprising once daily administration of a modified release solid oral dosage form.
Type:
Application
Filed:
August 28, 2018
Publication date:
July 11, 2019
Applicant:
PRILENIA THERAPEUTICS DEVELOPMENT LTD.
Inventors:
Daniella Licht, Ioana Lovinger, Laura Yehudit Guilatt, Merav Bassan
Abstract: The invention provides a method of treating a subject afflicted with a dystonia, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to treat the subject.
Type:
Application
Filed:
February 24, 2019
Publication date:
June 27, 2019
Applicant:
PRILENIA THERAPEUTICS DEVELOPMENT LTD.
Inventors:
Michael HAYDEN, Spyridon PAPAPETROPOULOS, Juha-Matti SAVOLA, Eli EYAL, Beth BOROWSKY, Igor D. GRACHEV, Mark Forrest GORDON
Abstract: A method of treating a human patient afflicted with Huntington's disease, comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine or a pharmaceutically acceptable salt thereof such that greater than 90 mg of pridopidine is administered to the patient per day.
Type:
Grant
Filed:
June 19, 2014
Date of Patent:
June 18, 2019
Assignee:
PRILENIA THERAPEUTICS DEVELOPMENT LTD.
Inventors:
Merav Bassan, Esther Lukasiweicz Hagai, Eli Eyal, Anna Kristina Sveinsdotter Teige Wickenberg